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ABSTRACT 
Sub-lethal concentrations of the organophosphate phenyl saligenin phosphate (PSP) inhibited the 
outgrowth of axon-like processes in differentiating mouse N2a neuroblastoma cells (IC50   2.5 
μM). A transient rise in the phosphorylation state of neurofilament heavy chain (NFH) was 
detected on Western blots of cell extracts treated with 2.5 μM PSP for 4 h compared to untreated 
controls, as determined by a relative increase in reactivity with monoclonal antibody Ta51 (anti-
phosphorylated NFH) compared to N52 (anti-total NFH). However, cross-reactivity of PSP-
treated cell extracts was lower than that of untreated controls after 24 h exposure, as indicated by 
decreased reactivity with both antibodies. Indirect immunofluorescence analysis with these 
antibodies revealed the appearance of neurofilament aggregates in the cell bodies of treated cells 
and reduced axonal staining compared to controls. By contrast, there was no significant change 
in reactivity with anti-α tubulin antibody B512 at either time point. The activation state of the 
MAP kinase ERK 1/2 increased significantly after  PSP treatment compared to controls, 
particularly at 4 h, as indicated by increased reactivity with monoclonal antibody E-4 (anti-
phosphorylated MAP kinase) but not with  polyclonal antibody K-23 (anti-total MAP kinase). 
The observed early changes were concomitant with almost complete inhibition of the activity of 
neuropathy target esterase (NTE), one of the proposed early molecular targets in 
organophosphate-induced delayed neuropathy (OPIDN). 
 
Keywords: Phenyl saligenin phosphate; Mouse N2a neuroblastoma; Axon outgrowth; 
Neurofilament heavy chain; Neuropathy target esterase; MAP kinase (ERK1/2). 
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1. Introduction 
 
Certain organophosphate compounds (OPs) are capable of inducing a delayed neurodegenerative 
condition in central and peripheral nervous system of man, birds and livestock [1-6]. This 
condition, which may arise up to 3 weeks after exposure to neuropathic OPs, is known as 
organophosphate-induced delayed neuropathy (OPIDN). Studies on animal models have shown 
that the onset of clinical signs of the disease is preceded by inhibition of neuropathy target 
esterase (NTE) and also by cytoskeletal disruption [4,5,7-10], suggesting that these lesions may 
represent key molecular events in the development of this delayed neurodegenerative condition. 
The ability to block the neurodegenerative effects of neuropathic OPs by Ca2+ channel blockers 
and calpain inhibitors also suggests that increased intracellular Ca2+  levels and calpain activation 
may be involved [11]. However, the precise molecular basis of OPIDN is poorly understood. 
 
For many years NTE has been regarded as the primary target for neuropathic OPs, although its 
inhibition in non-neuronal cells and tissues that are not damaged has raised doubts about a direct 
role for its esterase activity in the pathogenesis of OPIDN. However, it has been shown that the 
ability to inhibit NTE alone is not sufficient to induce the chain of events leading to OPIDN. 
Indeed, a modification that involves an increase in negative charge at the active site is proposed 
to occur before the induction of OPIDN, a phenomenon known as ageing [5,12,13]. 
Furthermore, recent work suggests that NTE may have important non-esterase functions, the 
alteration of which may in some way trigger a series of molecular events leading to Ca2+ release 
and calpain activation [13].  
 
A number of other studies have shown that there is a major rearrangement of the axonal 
cytoskeleton and substantial changes in the phosphorylation states of key cytoskeletal proteins in 
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microtubule and neurofilament networks within 24 hours of exposure to neuropathic OPs [1, 7-
10]. However, the ability of OPs to disrupt specific cell signalling pathways has not yet been 
thoroughly investigated. Moreover, there is disagreement as to the exact nature of the changes 
[8,9] and the relationship between NTE inhibition and cytoskeletal alterations remains to be 
established. 
 
Detailed in vivo studies of the molecular basis of OPIDN are hampered by the costly and time-
consuming nature of experiments on large numbers of laboratory animals. This has led to the 
development of in vitro alternatives to animal studies and, in particular, the use of cultured nerve 
cells [14]. One approach has been to measure the effects of neuropathic and non-neuropathic 
OPs on NTE activity in neuroblastoma cell lines [15-18], which is potentially very useful in the 
screening of OPs for their potential to cause OPIDN. A second approach has been to study the 
effects of neuropathic and non-neuropathic OPs on the outgrowth of neurites by neuronal and 
glial cells induced to differentiate in vitro [19-23]. Interestingly, the neuropathic properties of 
protoxiciants can be enhanced in cultured cells either by bromination [15,16] or by co-incubation 
with NADPH-activated rat liver microsomes [15,16,20], suggesting that in vitro cellular models 
are able to simulate at least some of the neurodegenerative effects of OPs in vivo. Furthermore, 
in a number of the above mentioned studies the authors have reported selective inhibition of 
neurite outgrowth by neuropathic OPs, although the involvement of NTE in the inhibition of 
neurite outgrowth remains to be established. 
 
Our work has focused on the sub-lethal effects of OPs on the outgrowth of axon-like processes 
by differentiating N2a cells. Our previous findings show that the neuropathic ortho isomer of 
tricresyl phosphate (TOCP) inhibits axon outgrowth to a greater extent than the non-neuropathic 
isomer triparacresyl phosphate [20]. This effect, which is most evident following shorter 
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exposure times, is enhanced by incubation in the presence of NADPH-activated microsomes. 
Since TOCP is thought to be metabolised into active (in terms of ability to induce OPIDN) 
congeners such as saligenin cyclic-O- tolyl phosphate (SCOTP) [24-27], our findings suggest 
that differentiating N2a neuroblastoma cells represent a useful model for mechanistic studies of 
the neurodegenerative effects of OPIDN-inducing OPs. As the exact nature of the microsomal 
activation products in vitro is not known, it is important to show that known in vivo metabolites 
are able to induce neuropathic changes in this cell model. The work presented here focuses on 
the effects of phenyl saligenin phosphate (PSP; a neuropathic homologue of SCOTP) on neurite 
outgrowth, cytoskeletal proteins, NTE activity and MAP kinase activation in vitro. 
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2. Materials and methods 
 
2.1. Cell lines and reagents 
 
Mouse N2a neuroblastoma cells were purchased from ICN (Thane, UK). Cell culture plastics 
were supplied by SLS Laboratory Supplies (Nottingham, UK). Cell culture reagents and 
monoclonal antibodies against α-tubulin (clone B512) and NFH (clone N52) were obtained from 
Sigma-Aldrich Co. Ltd. (Poole, UK). Mouse anti-phospho ERK 1/2 (E-4) and rabbit anti-total 
ERK 1/2 (K-23) were purchased from Santa Cruz Biotechnology (Santa Cruz, USA). 
Fluorescein isothiocyanate (FITC)-conjugated and alkaline phosphatase-conjugated rabbit anti-
mouse immunoglobulin and goat anti-rabbit immunoglobulin secondary antibodies were 
obtained from DakoCytomation (Ely, UK). Monoclonal antibody Ta51 hybridoma culture 
supernatant [28] was a gift from Dr M. Carden (Biological Laboratory, University of Kent). 
Phenyl saligenin phosphate (PSP) synthesis was based on the method of SCOTP synthesis by 
Nomeir and Abou-Donia [29] using phenyl phosphorodichloridate in place of o-cresyl 
phosphorodichloridate. Chemical purity was confirmed by NMR and mass spectrometry.  
 
2.2. Maintenance of cultured cells  
 
The cells were grown in T-25 flasks at 37 °C in a humidified atmosphere of 5% CO2 - 95% air, 
in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum, 1 mM 
glutamine, penicillin G (100 units/ml) and streptomycin (100 μg/ml). They were maintained in 
the logarithmic phase of growth and passaged at 4-5 day intervals. 
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2.3. Induction and assessment of N2a cell differentiation 
 
Cells were taken at 60 - 80 % confluence, seeded in 24-well culture dishes at a density of 50,000 
cells/ml in 0.5 ml growth medium, and induced to differentiate by serum withdrawal and the 
addition of dibutyryl cAMP, as described previously [19,20,30].  They were then incubated for 
up to 24 h in the presence and absence of PSP to yield various final concentrations, as indicated 
in Results. Cell growth and viability were assessed under all experimental conditions employed 
by the reduction of methyl blue tetrazolium using the method of Denizot and Lang [31].  
For morphological assessment, at the end of the incubation period the cells were fixed and 
stained with Coomassie brilliant blue and the outgrowth of axon-like processes was determined 
using an inverted light microscope, as described previously [19,20,30]. This involved the 
quantification of axon-like processes, defined according to Keilbaugh et al. [32] as neurites 
greater than 2 cell body diameters in length. Small extensions were defined as outgrowths 
between 0.5 and 2 cell body diameters in length and the numbers of cells with round or flattened 
morphology were also determined. 
 
2.4. Western blot analysis 
 
For immunoblot analysis, N2a cells were induced to differentiate in the presence and absence of 
PSP as described above, except that they were seeded in to 10 ml of growth medium in T-25 
flasks. Cell monolayers were then solubilised by boiling in electrophoresis sample buffer 
comprising 62.5 mM Tris, 2% w/v sodium dodecyl sulphate (SDS), 10% w/v glycerol, 5% w/v 
β-mercaptoethanol and 0.002% w/v bromophenol blue or in 0.5% w/v SDS. Protein was 
estimated on acetone-precipitated cell extracts by the method of Lowry et al. [33] with minor 
modifications, using bovine serum albumin (BSA) as the standard. Equal amounts of cell protein 
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were subjected to gel electrophoresis in the presence of SDS (SDS-PAGE) using a 7.5% 
polyacrylamide resolving gel overlaid with a 4% stacking gel [34]. 
 
Separated proteins were then electrophoretically transferred onto nitrocellulose membrane filters 
[35]. The resultant Western blots were blocked with 3% w/v BSA in Tris-buffered saline 
(BSA/TBS) and then probed overnight at 4°C with appropriate dilutions of primary antibodies in 
BSA/TBS [20]. These included mouse monoclonal anti-α-tubulin (B512), mouse monoclonal 
anti-total neurofilament heavy chain (N52) or rat monoclonal anti-phosphorylated neurofilament 
heavy chain (Ta51). Alternatively, they were probed with mouse monoclonal anti-
phosphorylated ERK1/2 MAP kinase (clone E-4) or rabbit polyclonal anti-total ERK 1/2 (K-23). 
After washing extensively with TBS/Tween-20, blots were probed with appropriate dilutions of 
secondary antibodies and enzyme substrates, as described previously [20]. Antibody reactivity 
on developed blots was quantified densitometrically using Quantiscan software (BioSoft) and 
values expressed as a percentage of their corresponding controls. The phosphorylation status of 
ERK 1/2 was also determined as the ratio between the levels of reactivity with anti-
phosphorylated ERK and anti-total ERK compared to controls. 
 
2.5. Indirect immunofluorescence staining 
 
N2a cells were induced to differentiate for 24 h in the presence and absence of 2.5 μM PSP. 
They were then fixed with methanol and stained with antibodies that recognise total 
neurofilament heavy chain (NFH) independent of its phosphorylation state (clone N52) or NFH 
phosphorylated in its KSP domain (clone Ta51) followed by FITC-labelled secondary 
antibodies, as described previously [19]. 
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2.6. Measurement of neuropathy target esterase activity 
 
For assays of cellular NTE activity, cells were induced to differentiate as above, except that 
they were seeded into 40 ml of growth medium in T-75 cell culture flasks. At the end of the 
incubation period, cells were harvested by centrifugation at 1200 g for 10 min, and then 
washed by resuspension and recentrifugation in PBS. Pellets were stored at - 20ºC until 
required. NTE activity was determined in homogenates of control (untreated) and PSP-treated 
cells by the absorbance difference for phenyl valerate hydrolysis between samples exposed to 
paraoxon only and those exposed to both paraoxon and mipafox, as previously described [36].  
 
2.7. Statistical analysis 
 
Unless indicated otherwise, axon outgrowth, NTE activity and densitometric peak areas of bands 
revealed on probed Western blots of cells/cell extracts following exposure to OPs were 
expressed as a percentage of control values ± S.E.M. When appropriate, the statistical 
significance of differences from corresponding controls was established using the Mann-
Whitney U-test for non-parametric distributions or by ANOVA, with 95% confidence limits. 
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2. Results 
 
Since our previous work suggested that metabolic activation of TOCP could enhance its ability 
to inhibit the outgrowth of axon-like processes [20], it was of interest to determine the direct 
effects of active congeners of TOCP on neurite outgrowth in the present work. Experiments were 
therefore carried out with PSP, a structural analogue of SCOTP that has the ability to cause 
OPIDN in vivo without the need for metabolic activation [37]. Preliminary work (not shown) 
indicated that PSP inhibited the outgrowth of axon-like processes at various exposure times 
between 4 and 48 h, with IC50 values all within the range of 2.2 to 3.0 μM. Accordingly, a 
concentration of 2.5 μM was adopted for subsequent experiments. As indicated in Fig. 1, there 
was an apparent decrease in the outgrowth of neurites compared to controls in cells induced to 
differentiate for 4 and 24 h in the presence of 2.5 μM PSP. Similar effects were observed at 8 h 
and 48 h time points (not shown). Quantitative assessment of cell morphology following 
treatment with this concentration of PSP confirmed that there was a statistically significant 
reduction in the outgrowth of axon-like processes compared to controls (Table 1). By contrast, 
no significant effect was observed on the number of smaller neurites (extensions) or on the 
proportion of round and flat cell (Table 1).  
 
In order to study the molecular basis of these effects in more detail, Western blots of extracts 
from cells induced to differentiate in the presence and absence of 2.5 μM PSP were probed with 
antibodies that recognise key proteins involved in the process of neurite outgrowth. These 
included antibodies against NFH (clones N52 and Ta51, which recognise total NFH and 
phosphorylated NFH, respectively), α-tubulin (clone B512) and MAP kinase (ERK1/2; 
monoclonal antibody E-4 and polyclonal antibody K-23, which recognise activated and total 
ERK 1/2, respectively). As shown in Fig. 2 and Table 2, cross-reactivity of an approximately 200 
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kDa polypeptide with N52 (which recognises NFH independently of its phosphorylation state) 
shows a slight but significant decrease compared to controls at 4 h and after 24 h exposure. By 
contrast, reactivity with Ta51 (which recognises a phosphorylated epitope in the KSP domain of 
NFH) was significantly higher than control values at 4 h, followed by a decline compared to 
control values at 24 h exposure. By contrast, reactivity of cell extracts with monoclonal anti-
tubulin antibody B512 showed no significant difference from controls at either time point. 
 
 In order to determine whether the observed relative increase in reactivity with Ta51 compared to 
N52 in PSP-treated cell extracts reflected altered activation of MAP kinase (ERK 1/2), of which 
NFH is a known substrate during neuronal cell differentiation [38,39], blots were also probed 
with antibodies against activated and total ERK. As shown in Fig. 2 and Table 2, total ERK 
levels were slightly lower than controls at 4 h exposure but showed no significant change from 
controls at 24 h. By contrast, reactivity of cell extracts with anti-phospho ERK antibody was 
240% of control values at 4 h and 157% of control values at 24 h, corresponding to 
phosphorylation ratios of 3.6 and 1.6, respectively. 
 
The possibility that the observed change in NFH phosphorylation in PSP-treated cells might 
cause neurofilament disruption was further investigated by indirect immunofluorescence 
staining. As shown in Fig. 3, differentiated cells exhibited relatively strong axonal staining 
(vertical arrows) with both monoclonal antibodies N52 and Ta51. By contrast, PSP-treated cells 
showed relatively strong aggregate staining (horizontal arrows) in the cell body with both 
antibodies and staining of axon-like processes was relatively weak. 
 
Since NTE inhibition is thought to be an early lesion occurring within hours of exposure to PSP 
both in vivo and in vitro, but its relationship to cytoskeletal changes or cell signalling is not yet 
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known, it was of interest to measure NTE activity at early time points in differentiating N2a 
cells. Indeed, the activity of NTE in extracts from differentiating N2a cells exposed for 4 h or 8 h 
to 2.5 μM PSP was greatly reduced to 2.6 ± 1.4 % and 6.3 ± 4.5 % of the corresponding control 
values, respectively (4 independent experiments). 
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4. Discussion 
 
The work presented here shows that PSP is able to inhibit the outgrowth of axon-like processes 
by differentiating N2a cells with no significant effect on the outgrowth of smaller processes or 
cell shape. Since PSP is an analogue of one of the main neuropathic metabolites of TOCP [37], 
the observed inhibition of neurite outgrowth is in good agreement with our previous work, in 
which the neuropathic effect of TOCP in vitro was enhanced by metabolic activation with 
NADPH activated rat liver microsomes [20]. It is also consistent with the findings from in vivo 
studies of the pathogenesis of OPIDN, in which PSP and other metabolites of TOCP are more 
effective than TOCP in the induction of OPIDN [1,2,20,21,23,32]. The fact that the longer (i.e. 
"axon-like") processes are more sensitive to PSP treatment in vitro agrees with previous studies 
using TCP (mixed isomers) and TOCP, in which the outgrowth of smaller processes was also 
unaffected [19,20]. These observations are also consistent with the finding that axons of longer 
neurons tend to be more vulnerable to neuropathic OPs in vivo [1]. 
 
Interestingly, the observation of decreased reactivity of PSP-treated cell extracts with N52 is in 
agreement with our previous findings for TOCP [20]. The fact that it is also in agreement with a 
more recent in vivo study using sciatic nerves of hens treated with TOCP [40] indicates that this 
cellular model is capable of predicting the pattern of in vivo delayed toxicity of OPs. Since the 
epitope recognised by N52 is independent of its phosphorylation state, this suggests that there 
may be a decrease in the levels of NFH at this time point. This could be attributed to increased 
degradation of NFH by proteases such as cathepsin D or calpain [41,42]. Indeed, activation of 
calpain has been shown to occur in response to OP treatment in vivo [11]. Alternatively, the 
reduced reactivity could be caused by decreased synthesis of NFH. In this respect, it has been 
shown that the OP pesticide chlorpyrifos is able to reduce the levels of DNA and protein 
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synthesis in vivo [43]. However, the OP compound diisopropyl phosphorofluoridate (DFP) 
causes an increase in levels of neurofilament mRNA [44], suggesting that some OPs are able to 
induce expression of NFH, although the levels of protein were not measured in that work. It may 
therefore be that structurally different groups of OPs are able to inhibit neurite outgrowth 
through a variety of mechanisms. 
 
Quantitative analysis of Western blots probed with Ta51, indicated that PSP induced a 
significant increase in reactivity concomitant with reduced levels of N52 reactivity (total NFH) at 
the 4-hour time point. Since Ta51 recognises NFH in a phosphorylation- dependent manner and 
the binding of N52 is independent of phosphorylation state, this result indicates an increase in the 
phosphorylation state of NFH at this time point. The subsequent decrease in Ta51 reactivity 
following 24 h exposure suggests that the increase in NFH phosphorylation at 4 h is transient. 
Furthermore, the levels of reactivity at 24 h exposure are similar to those found in TOCP-treated 
cells [20] indicating that sustained inhibition of neurite outgrowth is associated with reduced 
levels of NFH. 
 
The fact that PSP but not TOCP, TCP or TPCP causes a transient increase in NFH 
phosphorylation suggests that PSP may have some distinct molecular targets compared to the 
other compounds and that increased NFH phosphorylation may require metabolic activation of 
TOCP. As mentioned in our previous work, smaller increases in the phosphorylation state of 
NFH may be masked by proteolytic degradation. Interestingly, Suwita et al. [10] demonstrated 
an increased level of in vitro Ca2+/calmodulin activated protein kinase-dependent 
phosphorylation of NFH in spinal cord neurofilaments isolated from TOCP-treated hens, 
suggesting that altered phosphorylation of NFH and other cytoskeletal proteins was an early 
event in the pathogenesis of OPIDN. This suggests that increased phosphorylation of 
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cytoskeletal proteins is a key early event following exposure to TOCP and, presumably, its 
activated metabolites in vivo. However, work by Jortner et al. [9] suggested that reactivity of the 
phosphorylated NFH specific antibody SMI31 with PSP-treated hen spinal cord neurofilaments 
was lower than controls between 4 days exposure and the onset of clinical OPIDN. This suggests 
that, if it occurs in vivo, the OP-induced increase in phosphorylation of NFH observed by Suwita 
et al. [10] is not sustained for more than a few days. 
 
The changes in NFH phosphorylation suggested that disruption of cell signalling pathways might 
occur following exposure to PSP. It was of particular interest to study the effects of this OP on 
the activation of the MAP kinase ERK 1/2, since this protein kinase is a convergence point of 
cell signalling events involved in neurite outgrowth and it is known to phosphorylate NFH 
[38,39]. The increase in reactivity of anti-activated (phosphorylated) ERK but not anti-total ERK 
antibody with cell extracts following 4 h exposure to PSP suggests that PSP treatment leads to 
increased ERK activation, which may account for the increased level of NFH phosphorylation at 
this time point. Reactivity with probed blots of extracts exposed to PSP for 24 h indicates a 
smaller increase in activation over control levels at this time point than at 4 h, possibly due to 
phosphatase activity or negative feedback phosphorylation of MAP kinase kinases such as MEK 
[45]. Thus, it may be that the decreased levels of NFH phosphorylation at 24 h occurs as a 
combination of both down regulation of ERK activation and the proteolytic degradation 
suggested earlier. 
 
A recognised early target for OPIDN-inducing OPs is NTE, although a link between NTE 
inhibition and cytoskeletal disruption had not been previously established in the differentiating 
N2a model. The almost complete loss of NTE activity observed at the 4 h time point in PSP-
treated differentiating N2a cells (Table 3) is similar to that observed by Ehrich et al. [46] who 
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used mitotic human neuroblastoma cells treated with 10 μM PSP. This result confirms that NTE 
inhibition is another key early event following exposure of differentiating N2a cells to PSP.  The 
precise way in which NTE inhibition and ageing are related to the observed changes in MAP 
kinase activation and NFH levels and phosphorylation is not yet known. It has been suggested 
that endoplasmic reticulum-associated NTE may have the ability to hydrolyse lipids or act as an 
ion channel [47,48]. It may therefore be that the disruption of these properties is involved in the 
response to OP exposure in this cellular system. 
 
In conclusion, the work presented in this paper shows that exposure of differentiating  
N2a cells to PSP causes selective inhibition of the outgrowth of axon-like processes.  This is the 
first demonstration that inhibition of neurite outgrowth in a differentiating neuronal cell system is 
associated with reduced NTE activity (i.e. a proposed early molecular target of OPs in vivo). In 
addition, it is the first report of transiently enhanced phosphorylation of KSP domains on NFH 
and increased MAP kinase activation in situ. Further work on differentiating N2a cells will help 
to unravel the critical early molecular events following intoxication with neuropathic OP 
compounds.  
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Fig. 1 Effects of PSP on the morphology of differentiating N2a cells 
N2a cells were induced to differentiate for 4 h (a, b) or 24 h (c, d) in the presence (b, d) and 
absence (a, c) of 2.5 μM PSP, as described in Materials and Methods. Shown are images of 
typical fields of cells viewed by phase contrast microscopy after 4 h differentiation (a, b) or 
using an inverted light microscope following methanol fixation and staining with Coomassie 
blue after 24 h differentiation (c, d). Bar represents 15 μm. 
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Incubation 
time  
 
Treatment 
 
Axons 
 
Extensions 
 
Round 
cells 
 
Flat 
cells 
 
 
4h 
 
CONTROL 
 
 
32.35 ± 2.2 
 
29 ± 1.1 
 
16 ± 0.5 
 
84 ± 0.5 
  
2.5 μM PSP 
 
 
13.2 ± 1.4* 
 
29 ± 1.1 
 
15 ± 0.6 
 
85 ± 0.6 
 
24h 
 
CONTROL 
 
 
35.9 ± 6.5 
 
24 ± 0.8 
 
19 ± 0.8 
 
81 ± 0.8 
  
2.5 μM PSP 
 
 
18.5 ± 1.1* 
 
28 ± 1.5 
 
25 ± 2.0 
 
75 ± 2.0 
 
 
 
Table 1 Effects of PSP on neurite outgrowth in differentiating N2a cells 
N2a cells were induced to differentiate for 4 or 24 h in the presence and absence of 2.5 μM PSP, 
stained with Coomassie blue and assessed for axon outgrowth, outgrowth of small extensions 
and round/flat cell morphologies, as described in Materials and methods. Data are expressed as 
number per 100 cells ± SEM from 4 independent experiments. Significance of differences from 
controls was determined by ANOVA (* p < 0.05).  
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          Exposure time  
         4h             24h 
      -       +      -         + 
 
                                           
 
Fig. 2 Western blotting analysis of extracts from N2a cells induced to differentiate in the 
presence and absence of PSP. N2a cells were induced to differentiate for 4 h or 24 h in the 
presence (+) and absence (-) of 2.5 μM PSP, as indicated, after which extracts were solubilised, 
separated by SDS-PAGE and transferred onto nitrocellulose membrane filters as described in 
Materials and Methods. Shown are Western blots of equal amounts of control and PSP-treated 
cell protein probed with antibodies that recognise total NFH (N52), phosphorylated NFH (Ta51), 
activated ERK (pERK), total ERK (ERK) and total α-tubulin (B512), followed by an appropriate 
alkaline phosphatase-conjugated secondary antibody. 
 
N52 
Ta51 
pERK 
ERK 
B512 
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______________________________________________________________________ 
               Exposure time  
    4 h            24 h 
   ____________________________________________________ 
Antibody                                Densitometric peak area  
                      (% control) 
______________________________________________________________________ 
 
N52    75.9  ± 10.4 *     74.2 ± 15.9      
Ta51   168.2 ± 24.1*     66.5 ± 24.3   
pERK   301.0 ± 27.4*    168.6 ± 7.6*  
ERK     82.9 ±  6.8*     102.8 ±  6.9    
B512     83.8 ± 11.2    104.7 ± 11.3   
Table 2   Effects of PSP on the levels of cytoskeletal proteins and ERK in N2a cells induced 
to differentiate in the presence and absence of PSP. N2a cells were induced to differentiate in 
the presence (+) and absence (-) of 2.5 μM PSP for 4h or 24 h (as indicated), solubilised, 
separated by SDS-PAGE and subjected to Western blotting as described in Materials and 
Methods. They were then probed with antibodies against total NFH (N52), phosphorylated NFH 
(Ta51), activated ERK (pERK), total ERK (ERK) and total α-tubulin (B512), as described in 
Materials and Methods. Densitometric analysis was performed using Quantiscan software. All 
values were normalised to the levels of α-tubulin reactivity and are expressed as mean % control 
values ± SEM for a minimum of 3 independent experiments. Asterisk indicates a significance of 
p < 0.05 compared to the corresponding control.
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Fig. 3 Effects of PSP on neurofilament heavy chain distribution in differentiating N2a cells. 
N2a cells were induced to differentiate for 24 h in the presence (b, d) and absence (a, c) of 3 μM 
PSP; they were then stained by indirect immunofluorescence using monoclonal antibodies N52 
and Ta51, which recognise total NFH (a, b) and NFH phosphorylated in its KSP domain (c, d), 
respectively. Downward arrows indicate the position of axon-like processes, horizontal arrows 
indicate cell body accumulation of NFH staining and the bar represents 10 μm. 
 
a b
c d
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